The aim of this study was to investigate the potential of combined MAO-B and tau binding of [18F]-THK5351 as a tool for differential diagnosis of neurodegenerative parkinsonian syndromes, i.e., PD, MSA, and PSP, in vivo. Here, MAPT is linked to Parkinson disease.